Premium
Erratum to “Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration”
Publication year - 2021
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.33544
Subject(s) - medicine , food and drug administration , cancer drugs , drug , drug approval , intensive care medicine , drug administration , cancer , pharmacology